ContraFect Corporation – NASDAQ:CFRX
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
ContraFect stock price monthly change
-80.54%
month
ContraFect stock price quarterly change
-93.57%
quarter
ContraFect stock price yearly change
-65.03%
year
ContraFect key metrics
Market Cap | N/A |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | 0.05 |
Price/Sales | N/A |
Price/Book | -0.04 |
PEG ratio | N/A |
EPS | -24.3 |
Revenue | N/A |
EBITDA | -39.62M |
Income | -22.02M |
Revenue Q/Q | -100% |
Revenue Y/Y | -100% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeContraFect stock price history
ContraFect stock forecast
ContraFect financial statements
| Dec 2022 | 0 | -15.21M | |
|---|---|---|---|
| Mar 2023 | 0 | 6.11M | |
| Jun 2023 | 0 | -7.56M | |
| Sep 2023 | 0 | -5.35M |
| 2025 | 0 | -151.84K |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 20679000 | 32.53M | 157.31% |
|---|---|---|---|
| Mar 2023 | 20552000 | 23.68M | 115.26% |
| Jun 2023 | 19252000 | 20.36M | 105.76% |
| Sep 2023 | 9125000 | 14.88M | 163.11% |
| Dec 2022 | -9.96M | 8.06M | 6.14K |
|---|---|---|---|
| Mar 2023 | -8.79M | 2.74M | 9.01M |
| Jun 2023 | -8.15M | 1.98M | 8.72M |
| Sep 2023 | -8.66M | 0 | -340K |
ContraFect alternative data
| Aug 2023 | 23 |
|---|---|
| Sep 2023 | 23 |
| Oct 2023 | 23 |
| Nov 2023 | 23 |
| Dec 2023 | 23 |
| Jan 2024 | 23 |
| Feb 2024 | 23 |
| Mar 2024 | 23 |
| Apr 2024 | 23 |
| May 2024 | 23 |
| Jun 2024 | 23 |
| Jul 2024 | 23 |
ContraFect other data
100.00%
+71.26%
of CFRX is owned by hedge funds
12
-25
93.50K
-47.80K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2019 | 355000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | LOW DAVID N. director | Common Stock, par value $0.0001 per share | 300,000 | N/A | N/A | ||
Purchase | SUCOFF CARY director | Common Stock, par value $0.0001 per share | 50,000 | N/A | N/A | ||
Purchase | MESSINGER MICHAEL officer: Chief Financial Officer | Common Stock, par value $0.0001 per share | 5,000 | $0.37 | $1,850 | ||
Sale | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 10 percent owner | Common Stock | 600,000 | N/A | N/A | ||
Sale | FOSUN INDUSTRIAL CO., LTD 10 percent owner | Common Stock | 600,000 | $2.04 | $1,224,000 | ||
Purchase | OTTO MICHAEL J. director | Common Stock, par value $0.0001 per share | 8,000 | N/A | N/A | ||
Purchase | RICCIARDI LISA director, officer.. | Common Stock, par value $0.0001 per share | 9,600 | $1.24 | $11,904 | ||
Purchase | BLECH ISAAC director | Common Stock, par value $0.0001 per share | 16,000 | N/A | N/A | ||
Purchase | GILMAN STEVEN C director | Common Stock, par value $0.0001 per share | 800 | $1.24 | $992 | ||
Purchase | GILMAN STEVEN C director | Warrants (Right to Buy) | 400 | $1.55 | $620 |
| Insider | Compensation |
|---|---|
Dr. Roger James Pomerantz F.A.C.P., FACP, M.D. (1957) Chairman, Chief Executive Officer & Pres | $1,370,000 |
| Dr. Cara M. Cassino (1962) Chief Medical Officer and Executive Vice President of R&D | $883,150 |
Mr. Michael Messinger CPA, CPA (1975) Chief Financial Officer | $623,300 |
-
When is ContraFect's next earnings date?
Unfortunately, ContraFect's (CFRX) next earnings date is currently unknown.
-
Does ContraFect pay dividends?
No, ContraFect does not pay dividends.
-
What is ContraFect's stock symbol?
ContraFect Corporation is traded on the NASDAQ under the ticker symbol "CFRX".
-
What is ContraFect's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ContraFect?
Shares of ContraFect can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are ContraFect's key executives?
ContraFect's management team includes the following people:
- Dr. Roger James Pomerantz F.A.C.P., FACP, M.D. Chairman, Chief Executive Officer & Pres(age: 68, pay: $1,370,000)
- Dr. Cara M. Cassino Chief Medical Officer and Executive Vice President of R&D(age: 63, pay: $883,150)
- Mr. Michael Messinger CPA, CPA Chief Financial Officer(age: 50, pay: $623,300)
-
How many employees does ContraFect have?
As Jul 2024, ContraFect employs 23 workers.
-
When ContraFect went public?
ContraFect Corporation is publicly traded company for more then 11 years since IPO on 12 Sep 2014.
-
What is ContraFect's official website?
The official website for ContraFect is contrafect.com.
-
Where are ContraFect's headquarters?
ContraFect is headquartered at 28 Wells Avenue, Yonkers, NY.
-
How can i contact ContraFect?
ContraFect's mailing address is 28 Wells Avenue, Yonkers, NY and company can be reached via phone at +91 42072300.
ContraFect company profile:
ContraFect Corporation
contrafect.comExchange:
NASDAQ
Full time employees:
23
Industry:
Biotechnology
Sector:
Healthcare
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
28 Wells Avenue
Yonkers, NY 10701
Yonkers, NY 10701
CIK: 0001478069
ISIN: US2123264093
CUSIP: 212326300
